目的 系統(tǒng)評(píng)價(jià)百令膠囊輔助治療糖尿病腎病的有效性和安全性。方法 計(jì)算機(jī)檢索PubMed、中國(guó)學(xué)術(shù)期刊全文數(shù)據(jù)庫(kù)（CNKI）、維普中文期刊全文數(shù)據(jù)庫(kù)（VIP）、中國(guó)生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(kù)（CBM）和萬(wàn)方數(shù)據(jù)庫(kù)中有關(guān)百令膠囊單獨(dú)或聯(lián)合其他藥物治療糖尿病腎病的臨床隨機(jī)對(duì)照試驗(yàn)（RCT），檢索時(shí)間從各數(shù)據(jù)庫(kù)建庫(kù)至2020年1月，按照納入與排除標(biāo)準(zhǔn)將篩選出的文獻(xiàn)進(jìn)行信息提取與質(zhì)量評(píng)價(jià)，采用RevMan5.3軟件進(jìn)行Meta分析。結(jié)果 共納入12篇RCTs，包括1 011例患者。Meta分析結(jié)果顯示：與對(duì)照組相比，百令膠囊能提高糖尿病腎病患者臨床療效［OR=5.04，95% CI=（3.16，8.03），P<0.000 01］，并降低尿白蛋白排泄率［SMD=-1.95，95% CI=（-2.74，-1.17），P<0.000 01］、血肌酐［SMD=-2.14，95% CI=（-3.57，-0.71），P=0.003］、24 h尿蛋白定量［SMD=-1.56，95% CI=（-2.45，-0.76），P=0.000 1］及空腹血糖［SMD=-0.52，95% CI=（-0.59，-0.47），P<0.000 01］；納入文獻(xiàn)均描述未發(fā)生不良反應(yīng)。結(jié)論 百令膠囊對(duì)糖尿病腎病有一定的療效且安全性較好，值得臨床借鑒；但由于本研究存在一定不足之處，故需質(zhì)量更高、樣本量較大的臨床研究進(jìn)一步證實(shí)。

Objective To systematically evaluate the efficacy and safety of Bailing Capsule for treating diabetic kidney disease (DKD). Methods Randomized controlled trials of Bailing Capsule in the treatment of DKD was collected by searching PubMed, CNKI, VIP, CBM and Wanfang databases by computer from inception to January 2020. Extract the information and evaluate the quality of the included literature. RevMan 5.3 software was used for Meta-analysis. Results A total of 12 studies involving 1 011 patients were included into the study. The results of meta-analysis showed that Bailing Capsule in the treatment of DKD can improve total effective rate[OR=5.04, 95%CI=(3.16, 8.03), P<0.000 01] and decrease urinary albumin excretion rate[SMD=-1.95, 95%CI=(-2.74, -1.17), P<0.000 01], serum creatinine[SMD=-2.14, 95%CI=(-3.57, -0.71), P=0.003], 24-hour urine protein[SMD=-1.56, 95%CI=(-2.45, -0.76), P=0.000 1] and fasting blood glucose[SMD=-0.52, 95%CI=(-0.59, -0.47), P<0.000 01]. No adverse reactions were reported in all the included literatures. Conclusion Bailing Capsule have certain effect to treat DKD and the safety is good, which is worthy of being learned in clinic. However, there are some deficiencies in this study, so more highquality and large sample clinical studies are still needed to further confirm.

R977

國(guó)家自然科學(xué)基金資助項(xiàng)目（81774304）；陜西省中醫(yī)藥管理局科研課題（2019-GJ-QT002）